Log in to your Inderes Free account to see all free content on this page.

Lundbeck

38.34

DKK

-4.15 %

Less than 1K followers

HLUN B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

-4.15%

-4.63%

-7.21%

-7.93%

-13.34%

+18.7%

+25.95%

+1.03%

+55.85%

Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.

Market cap

38.18B DKK

Turnover

17.84M DKK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

26.3.

2025

General meeting '25

27.3.

2025

Annual dividend

14.5.

2025

Interim report Q1'25

All

Press releases

ShowingAll content types

Regulatory press release6 hours ago

H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 26 March 2025 at the company's registered office

Press release3/13/2025, 8:00 AM

H. Lundbeck A/S: Rxulti[®] (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older

Press release3/10/2025, 8:01 AM

H. Lundbeck A/S: Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release2/25/2025, 9:00 AM

To the shareholders of H. Lundbeck A/S

Regulatory press release2/21/2025, 12:27 PM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Press release2/12/2025, 8:00 AM

H. Lundbeck A/S: Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA

Regulatory press release2/5/2025, 3:40 PM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Regulatory press release2/5/2025, 6:46 AM

H. Lundbeck A/S: Lundbeck Annual Report 2024

Regulatory press release2/5/2025, 6:23 AM

H. Lundbeck A/S: Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER)

Regulatory press release2/4/2025, 4:10 PM

H. Lundbeck A/S: Lundbeck announces changes to the Board of Directors

Press release1/30/2025, 8:00 AM

H. Lundbeck A/S: Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies

Regulatory press release1/9/2025, 1:07 PM

H. Lundbeck A/S: Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the treatment of adults with PTSD

Press release12/5/2024, 12:00 PM

H. Lundbeck A/S: Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations

Press release12/3/2024, 7:00 AM

H. Lundbeck A/S: Efficacy of Vyepti highlighted by new clinical trial results in severe migraine

Press release12/2/2024, 2:08 PM

H. Lundbeck A/S: Lundbeck completes acquisition of Longboard

Regulatory press release11/28/2024, 6:56 AM

H. Lundbeck A/S: Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled

Press release11/27/2024, 7:00 AM

H. Lundbeck A/S: Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy

Regulatory press release11/13/2024, 6:29 AM

H. Lundbeck A/S: Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024

Regulatory press release10/31/2024, 11:44 AM

H. Lundbeck A/S: Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention

Press release10/23/2024, 7:01 AM

H. Lundbeck A/S: Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.